What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.
Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm sitting on a nice gain of 57%, a little higher than AbbVie's year-to-date gain because of the timing of when I bought the stock.
Now that 2017 is drawing to an end, though, it's time to focus on the new year. Will AbbVie's success continue into 2018? Here's what I think investors should expect from the drugmaker next year.
Source: Fool.com
AbbVie Inc. Aktie
215,60 €
-0,69 %
Die AbbVie Inc. Aktie ist ein klarer Community-Favorit: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Mit einem Kursziel von 230 € für AbbVie Inc. ist ein leichter Anstieg gegenüber dem aktuellen Kurs von 215.6 € zu erwarten.
